Most Read Articles
3 days ago
Combining the DASH (Dietary Approaches to Stop Hypertension) diet with low sodium intake reduces systolic blood pressure (SBP) in individuals with pre- and stage 1 hypertension, with progressively higher reductions at greater levels of baseline SBP, a recent study has shown.
Tristan Manalac, Yesterday
Major depressive disorder (MDD) appears to be more prevalent in females than in males, particularly in those who are divorced or widowed, a recent study from Singapore has found.
6 days ago
Cognitive deficits in bipolar disorder are neurodevelopmental rather than neurodegenerative in nature, a recent study has reported. Furthermore, cognitive impairment in bipolar patients appears to be stable, in the majority at least.
3 days ago
Tadalafil may not be effective for reducing the decline in ambulatory ability in boys with Duchenne muscular dystrophy (DMD), as shown in a recent study.

Outcomes in BPS/IC better with intravesical chondroitin sulphate vs hyaluronic acid

26 Jul 2017

Intravesical chondroitin sulphate (CS) is superior to intravesical hyaluronic acid (HA) in the treatment of bladder pain syndrome (BPS)/interstitial cystitis (IC), improving 24-hour frequency, nocturia and interstitial cystitis problem index (ICPI), according to a study.

A total of 42 patients with BPS/IC were randomized equally to receive either CS (mean age 47.10) and HA (mean age 48.90). Assessments for visual analogue pain scale (VAS), interstitial cystitis symptom index (ICSI), ICPI, voiding diary for frequency/nocturia and mean urine volume per void were performed at baseline and after 6 months. All patients had initial potassium sensitivity test (PST). Wilcoxon and Mann-Whitney U tests were used for statistical analysis.

Prior to treatment, Parson’s test returned positive in more than half (64.3 percent) of the patients overall, with no between-group difference. Outcomes including VAS of pain, ICSI, ICPI, frequency at 24 hours and nocturia improved significantly in both treatment groups. However, the improvements were found to be greater with intravesical CS vs HA, especially 24-hour frequency, nocturia and ICPI (p<0.05). No severe adverse effects were reported.

BPS/IC is a chronic pain syndrome characterized by pain and discomfort in the bladder, with associated urgency and urinary frequency. The mechanisms underlying the syndrome’s development are said to involve the urothelium/transitional epithelium, with the protective layer of glycosaminoglycans (GAG) on the surface of the urothelial cells shown to be defective in some BPS/IC patients. The GAG layer—which constitutes HA, CS, heparin sulphate, dermatan sulphate and keratin sulphate—particularly provides a barrier against solutes in the urine. [Transl Androl Urol 2015;4:629–637]

In the management of BPS/IC, intravesical therapies have the advantage of targeting the bladder, allowing high drug concentrations and minimizing systemic side effects. In contrast, a major advantage is that delivery of the agent requires instrumentation of the urethra and bladder, potentially exacerbating pain and increasing the risk of urinary tract infection.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
3 days ago
Combining the DASH (Dietary Approaches to Stop Hypertension) diet with low sodium intake reduces systolic blood pressure (SBP) in individuals with pre- and stage 1 hypertension, with progressively higher reductions at greater levels of baseline SBP, a recent study has shown.
Tristan Manalac, Yesterday
Major depressive disorder (MDD) appears to be more prevalent in females than in males, particularly in those who are divorced or widowed, a recent study from Singapore has found.
6 days ago
Cognitive deficits in bipolar disorder are neurodevelopmental rather than neurodegenerative in nature, a recent study has reported. Furthermore, cognitive impairment in bipolar patients appears to be stable, in the majority at least.
3 days ago
Tadalafil may not be effective for reducing the decline in ambulatory ability in boys with Duchenne muscular dystrophy (DMD), as shown in a recent study.